New drug trio aims to replace chemo for aggressive lymphoma
NCT ID NCT07502872
First seen Apr 10, 2026 · Last updated May 23, 2026 · Updated 9 times
Summary
This study tests a combination of three targeted drugs (polatuzumab vedotin, glofitamab, and tafasitamab) as a first treatment for people with aggressive B-cell lymphomas. The goal is to see if this chemo-free approach can shrink tumors effectively while causing fewer side effects. About 30 adults with newly diagnosed diffuse large B-cell or high-grade B-cell lymphoma will take part. The trial is not yet recruiting.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LYMPHOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Rhode Island Hospital
Providence, Rhode Island, 02903, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.